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Abstract
Background and aims Patients with liver cirrhosis may be
at risk for potential drug-drug interactions (pDDIs) and/or
adverse drug reactions (ADRs) due to the severity of their
disease and comorbidities associated with polypharmacy.
Methods We performed a cross-sectional retrospective
study including 400 cirrhotic patients and assessed
diagnoses, medication patterns, pDDIs, and ADRs at
hospital admission.
Results The median (range) age of the patients was 60 (21–
88) years; 68.5% were male. They had a total of 2,415
diagnoses, resulting in 6 (1–10) diagnoses per patient.
Frequent were diagnoses of the digestive system (28.4%),
circulatory system (14.2%), blood and blood-forming
organs (8.7%), and psychiatric disorders (7.5%); 60.7% of
the diagnoses were not liver-associated. The median
number of drugs per patient was 5 (0–18), whereof 3 (0–
16) were predominantly hepatically eliminated. Drugs were
primarily indicated for gastrointestinal, cardiovascular, or
nervous system disorders, reflecting the prevalent diagno-
ses. In 112 (28%) patients, 200 ADRs were detected,
mainly associated with spironolactone, torasemide, furose-
mide, and ibuprofen. In 86 (21.5%) patients, 132 pDDIs
were detected. Seven of these pDDIs were the direct cause
of 15 ADRs, whereof 3 resulted in hospital admission.
Patients with ADRs were older, had more comorbidities,
were treated with more drugs, and had a worse renal
function and more pDDIs than patients without ADRs.
Conclusions Pharmacotherapy is complex in cirrhotic
patients. Hepatologists should know the principles of dose
adjustment in cirrhosis and renal failure, but also the most
important pDDIs of the drugs used to treat liver disease and
comorbidities in this population.
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Abbreviations
pDDIs Potential drug-drug interactions
ADRs Adverse drug reactions
NSAIDs Nonsteroidal anti-inflammatory drugs
Q0 Extrarenal elimination fraction
ATC code Anatomical Therapeutic Chemical Classifica-
tion System
ACE Angiotensin-converting enzyme
HSCT Hematopoietic stem cell transplantation
RAAS Renin angiotensin aldosterone system
SSRI Selective serotonine reuptake inhibitor
COX Cyclooxygenase
Introduction
Liver cirrhosis remains a frequent cause of morbidity and
mortality in most countries, including countries in Europe.
Between 1997 and 2001, the yearly mortality rate due to
liver cirrhosis was between 9.7 (Netherlands) and 43.5
Electronic supplementary material The online version of this article
(doi:10.1007/s00228-011-1105-5) contains supplementary material,
which is available to authorized users.
C. C. Franz : S. Egger :C. Born :A. E. Rätz Bravo :
S. Krähenbühl (*)
Division of Clinical Pharmacology and Toxicology,
University Hospital,
4031 Basel, Switzerland
e-mail: kraehenbuehl@uhbs.ch
A. E. Rätz Bravo
Regional Pharmacovigilance Center, University Hospital,
Basel, Switzerland
Eur J Clin Pharmacol (2012) 68:179–188
DOI 10.1007/s00228-011-1105-5
(Austria) per 100,000 males and between 5.6 (Sweden) and
16.7 (Austria) per 100,000 females [1].
Since the liver plays a crucial role in the metabolism
of endogenous and exogenous substances, impaired
hepatic function may influence the pharmacokinetics of
drugs used in cirrhotic patients. The absorption process
may be altered [2, 3] and bioavailability may be increased
due to porto-systemic shunting [2, 4]. The free fraction
and possibly also the free concentration of highly protein-
bound drugs is increased in patients with hypoalbumine-
mia [2]. Finally, hepatic drug clearance is usually
decreased due to lower hepatic blood flow [2, 5] and
decreased activity of phase I enzymes [2, 6, 7]. Pharma-
codynamic changes are also prevalent in patients with
liver cirrhosis. Increased sensitivity has been shown for
central effects of morphine [8] and benzodiazepines [9]
and for renal adverse effects of nonsteroidal anti-
inflammatory drugs (NSAIDs) [10].
All of these factors can potentially influence the
effectiveness of a drug and/or the likelihood that a drug is
causing adverse reactions. Adverse drug reactions (ADRs)
may further increase morbidity and mortality in patients
with liver disease.
The current study had several aims concerning drug
treatment of patients with liver cirrhosis. First, we wanted
to find out which drugs are commonly prescribed in this
group of patients. Secondly, we investigated the quantity
and severity of potential drug-drug interactions (pDDIs) in
these patients. Thirdly, we identified the ADRs. For this
purpose, we characterized the medication pattern of 400
patients with liver cirrhosis and assessed the prevalence of
pDDIs and ADRs at hospital admission.
Methods
Patients
In the present cross-sectional, retrospective study, we
included 400 patients with liver cirrhosis diagnosed by
liver histology and/or typical clinical, sonographic, and
computer tomographic signs. They were hospitalized at the
University Hospital, Basel, Switzerland, between January
2002 and December 2007. The protocol of the study was
accepted by the cantonal Ethics Committee.
Data collection
For each patient, demographic and clinical data, diagnoses,
drugs administered, characteristics of the drugs adminis-
tered (dosage and extrarenal elimination fraction, Q0), and
pDDIs and ADRs [11] were collected at hospital admission.
Creatinine clearance was calculated by the Cockcroft Gault
equation [12]. Severity of liver cirrhosis was classified by
the Child Pugh Score [13]. Drugs were grouped according
to the Anatomical Therapeutic Chemical Classification
System (ATC code). Drugs with a Q0≥0.5 were defined as
primarily hepatically eliminated. Potential DDIs were
determined by screening the drug profiles using the online
version of DRUG-REAX (Micromedex® 1.0 Healthcare
Series, http://www.micromedex.com). Only pDDIs with
moderate or major severity were considered. All ADRs
were classified with a definite, probable, or possible
causality rating as described previously [14].
Statistical analysis
The data were descriptively analyzed using Excel and/or
SPSS (version 15.0). Comparisons between patients with
ADRs and those without ADRs were performed using
Student’s t-test or the chi-squared test without correction
for repetitive testing. A significance level of 5% was
chosen.
Results
Patient characteristics
All patients studied were adults with males being more
prevalent than females (supplementary Table 1). Most
patients were in the Child Pugh classes B and C. The
most frequent cause of liver cirrhosis was alcohol
(69.8%), followed by viral hepatitis (13.5%) or a
combination of both (9.7%). Almost 20% of the patients
died during hospitalization, reflecting the severity of this
disease.
The patients had a total number of 2,415 diagnoses at
hospital admission, resulting in a median number of 6 (1–
10) diagnoses per patient (supplementary Table 2). Most
common were diseases of the digestive (28.4% of all
diagnoses) or circulatory system (14.2%) as well as
diseases of the blood and blood-forming organs (8.7%)
and psychiatric disorders (7.5%). Approximately 40% of all
diagnoses were associated with liver cirrhosis, e.g., spon-
taneous bacterial peritonitis, esophageal varices, and variceal
bleeding.
Medication at hospital admission
The patients had a total of 1,999 drugs at hospital
admission (Table 1). The median number of drugs per
patient was 5 (0–18); a median of 3 (0–16) were
predominantly hepatically eliminated. Most prevalent were
drugs affecting the alimentary tract and metabolism, mainly
vitamins and proton pump inhibitors, as well as drugs for
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Table 1 Drugs at hospital admission for patients with liver cirrhosis (n=400 patients)
Number of drugs (% of patients
receiving corresponding drug)
Number of drugs with Q0 ≥ 0.5a (% of
patients receiving corresponding drug)
Number of drugs at hospital admission 1,999 1,360
Drugs per patient at hospital admissionb 5 (0–18) 3 (0–16)
Alimentary tract and metabolismc 650 255
Vitaminsc 207 6
Thiamine 89 (22.3%) 0
Proton pump inhibitors 154 (38.5%) 154 (38.5%)
Osmotically acting laxatives 83(20.8%) 0
Blood glucose–lowering drugs (excl. insulins)c 65 38
Magnesium 33 (8.3%) 0
Insulins and analogues 27 (6.8%) 27 (6.8%)
Calcium 27 (6.8%) 0
Propulsives 12 (3.0%) 12 (3.0%)
Potassium 11 (2.8%) 0
Cardiovascular systemc 633 532
Potassium-sparing diureticsd 160 (40.0%) 160 (40.0%)
Loop diuretics (high ceiling) 157 (39.3%) 127 (31.8%)
Betablockers 146 (36.5%) 134 (33.5%)
Propranolol 78 (19.5%) 78 (19.5%)
ACE inhibitors 34 (8.5%) 8 (2.0%)
Calcium antagonists 25 (6.3%) 25 (6.3%)
Statins 23 (5.8%) 23 (5.8%)
Angiotensin receptor blockers 19 (4.8%) 19 (4.8%)
Thiazides 19 (4.8%) 0
Organic nitrates 12 (3.0%) 12 (3.0%)
Amiodarone 7 (1.8%) 7 (1.8%)
Nervous systemc 270 257
Benzodiazepines and related drugs 102 (25.5%) 102 (25.5%)
Lorazepam 28 (7.0%) 28 (7.0%)
Zolpidem 27 (6.8%) 27 (6.8%)
Oxazepam 14 (3.5%) 14 (3.5%)
Diazepam 13 (3.3%) 13 (3.3%)
Opioids 58 (14.5%) 58 (14.5%)
Methadone 29 (7.3%) 29 (7.3%)
Antidepressants, excl. SSRIe 30 (7.5%) 30 (7.5%)
SSRI 21 (5.3%) 21 (5.3%)
Neuroleptics 17 (4.3%) 15 (3.8%)
Antiepileptics 16 (4.0%) 10 (2.5%)
Dopaminergic agents 8 (2.0%) 8 (2.0%)
Blood and blood-forming organsc 154 96
Phytomenadione 44 (11.0%) 44 (11.0%)
Platelet aggregation inhibitors (incl. aspirin low dose) 30 (7.5%) 30 (7.5%)
Iron 26 (6.5%) 0
Oral anticoagulants 21 (5.3%) 21 (5.3%)
Heparins 15 (3.8%) 2 (0.5%)
Folic acid 13 (3.3%) 0
Musculoskeletal systemc 93 89
NSAIDs 28 (7.0%) 28 (7.0%)
Paracetamol 23 (5.8%) 23 (5.8%)
Eur J Clin Pharmacol (2012) 68:179–188 181
the cardiovascular system, primarily potassium-sparing
diuretics, loop diuretics, and betablockers. Approximately
10% of all patients were treated with an angiotensin-
converting enzyme (ACE) inhibitor. The most frequent
drugs for the nervous system were benzodiazepines and
benzodiazepine-related drugs as well as opioids. Eleven
percent of the patients were treated with phytomenadione,
7.5% with platelet-aggregation inhibitors, and 5% with oral
anticoagulants. Astonishingly, 11% of the patients were
treated with a COX inhibitor (NSAIDs, analgesic aspirin, or
COX-2 inhibitor).
About 68% of all administered drugs were eliminated
primarily hepatically (Q0≥0.5).
pDDIs and ADRs at hospital admission
In 21.5% of all patients, a median of 1 (1–5) pDDI was
detected (Table 2). Most prevalent possible adverse reac-
tions due to pDDI were hyperkalemia (potassium-sparing
diuretics, ACE inhibitors, and potassium chloride), hypo-
glycemia (betablockers combined with insulin, sulfonylureas,
and/or repaglinide), increased bleeding risk (anticoagulants
such as dalteparin or phenprocoumon combined with
NSAIDs), respiratory depression (benzodiazepines combined
with opiates or phenobarbital), and cardiac problems (cardiac
depression, QT prolongation). Of all pDDIs, 12.9% resulted in
an ADR.
ADRs were detected in 28% of the patients at entry
(Table 3). Relative to the number of patients in each Child
Pugh class, patients in class Child Pugh A were more
frequently affected by ADRs (35.7% of patients) than those
in class Child Pugh B (26.1%) or Child Pugh C (26.6%).
Nonetheless, most ADRs (43.0%) occurred in patients with
liver cirrhosis Child Pugh C. The drugs most frequently
associated with an ADR were spironolactone, torase-
mide, furosemide, and ibuprofen. Most frequently,
ADRs resulted in metabolic disorders (mainly hyper-
kalemia or hyponatremia associated with diuretics and/or
ACE inhibitors), in gastrointestinal bleeding (associated
with the use of NSAIDs or oral anticoagulants), and in
urinary system disorders (mainly worsening renal func-
tion due to the use of diuretics and/or ACE inhibitors).
Five percent of all ADRs affected the liver and/or the
biliary system.
Sixteen ADRs (8%) were the cause of hospital admis-
sion. These ADRs consisted of gastrointestinal bleeding
associated with low dose aspirin, ibuprofen, or phenpro-
coumon; hyperkalemia associated with spironolactone or
perindopril; and worsening renal function or ascites
accumulation associated with ibuprofen. Fifteen ADRs
Table 1 (continued)
Number of drugs (% of patients
receiving corresponding drug)
Number of drugs with Q0 ≥ 0.5a (% of
patients receiving corresponding drug)
Allopurinolf 14 (3.5%) 14 (3.5%)
Aspirin, analgesic 8 (2.0%) 8 (2.0%)
COX-2 inhibitors 7 (1.8%) 7 (1.8%)
Respiratory systemc 75 43
Anti-infectives for systemic usec 63 30
Antiviralsc 38 20
Antibacterials 25 (6.3%) 10 (2.5%)
Fluoroquinolones 9 (2.3%) 4 (1.0%)
Systemic hormonal preparations, excl. sex hormones and insulinsc 31 31
Corticosteroids 16 (4.0%) 16 (4.0%)
Thyroid hormones 13 (3.3%) 13 (3.3%)
Antineoplastic and immunomodulating agentsc 15 10
Genito-urinary system and sex hormonesc 10 9
Variousc 5 5
a Only drugs with known Q0 included
b Data are presented as median (range)
c One individual patient may have >1 drug of the corresponding group, % not calculated
d Spironolactone accounts for 97.5% of this group. It is mainly converted to active metabolites (the two major ones being canrenone and 7-alpha-
thiomethylspironolactone), which are primarily renally eliminated
e Including tri-, tetracyclic antidepressants, and venlafaxine
f Allopurinol is rapidly converted by the liver to the slightly less active oxypurinol, which is renally eliminated. Dosage adjustment is necessary in
both patients with liver and renal insufficiency
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(7.5%) resulted from a DDI; among them five patients with
bleeding disorders (gastrointestinal bleeding, epistaxis,
anemia), four patients with hyperkalemia, three patients
with cardiovascular disorders (hypotension, bradycardia,
torsade de pointes) as well as one patient each with a
psychiatric disorder, somnolence, and collapse. Three DDI-
associated ADRs were the reason for hospital admission,
namely gastrointestinal bleeding due to the combination of
aspirin (100 mg/day) and phenprocoumon, symptomatic
bradycardia due to the combination of amiodarone and
propranolol, and hyperkalemia due to the combination of
spironolactone and perindopril.
The 36 NSAIDs prescribed (NSAIDs and analgesic
aspirin) were associated with 24 ADRs in 18 patients
(50% of all patients with a NSAID) (Fig. 1). The most
prevalent ADRs due to NSAIDs were gastrointestinal
bleeding (14/24), bleeding-associated anemia (3/24),
exacerbation of ascites (2/24), and thrombocytopenia
(2/24). The 53 ACE inhibitor or sartan prescriptions
resulted in 20 ADRs in 10 patients (19% of patients
treated with an ACE inhibitor or sartan, Fig. 1).
Symptoms observed were worsening renal function (6/
20), syncope (4/20), hyperkalemia (3/20), hyponatremia
(3/20), and hypotension (2/20). In contrast, of 146
Table 2 Major and moderate pDDIs in patients with liver cirrhosis (n=400 patients)
DDI/potential outcome Number of pDDIs Interacting drugs (number of cases)
Total pDDIs 132 (100%)
Major pDDIs 56 (42.1%)
Moderate pDDIs 76 (57.9%)
Number of different pDDIs 91
Number of patients
with ≥1 pDDI
86 (21.5% of all patients)
pDDIs per patienta, b 1 (1–5)
DDIs resulting in an ADR 17 (12.9% of all pDDIs)
Hyperkalemia 24 (18.2%) Major: Potassium-sparing diuretics + ACE inhibitors (9); potassium
chloride + spironolactone (4), potassium chloride + lisinopril (1)
+ risk for nephrotoxicity 9 (6.8%) Moderate: Spironolactone + valsartan (1)
Moderate: Potassium-sparing diuretics + NSAID (9)
Hypoglycemia 23 (17.4%) Moderate: Betablocker + insulin (14), betablocker + sulfonylureas (8),
betablocker + repaglinide (1)
Increased bleeding risk 17 (12.9%) Major: Dalteparin + acetylsalicylic acid (low dose) (1), dalteparin +
clopidogrel (1), dalteparin + phenprocoumon (1), dalteparin + ibuprofen (1),
acetylsalicylic acid (low dose) + phenprocoumon (2),
acetylsalicylic acid (low dose) + venlafaxine (1)
Moderate: Phenprocoumon + allopurinol (3), phenprocoumon + amiodarone (3),
phenprocoumon + diclofenac (1), acetylsalicylic acid (low dose) + verapamil (2),
acetylsalicylic acid (low dose) + ibuprofen (1)
Respiratory depression 10 (7.6%) Major: Benzodiazepines + opiates (7), benzodiazepines + phenobarbital (2),
fentanyl + hydrocodone (1)
Cardiac depression 9 (6.8%) Major: Betablocker + calcium antagonist (4), betablocker + amiodarone (2)
Moderate: Digoxin + betablocker (3)
QT prolongation 7 (5.3%) Major: Amitriptyline + sulfamethoxazole, trimethoprim (2), ciprofloxacin +
propafenone (1), fluoxetine + haloperidol (1), fluoxetine + methadone (1),
risperidone + tramadol (1), trimipramine + venlafaxine (1)
Digoxin toxicity 6 (4.5%) Major: Digoxin + hydrochlorothiazide (2),
digoxin + spironolactone (2), digoxin + amiodarone (1)
Moderate: Digoxin + furosemide (1)
Altered methadone exposure 6 (4.5%) Moderate: Methadone + HIV protease inhibitor (4), methadone + efavirenz (2)
Serotonin syndrome 4 (3.0%) Major: Mirtazapine + fluoxetine (1), mirtazapine + tramadol (1),
mirtazapine + venlafaxine (1), tramadol + venlafaxine (1)
Reduced efficacy of levodopa 4 (3.0%) Moderate: Levodopa + iron (2), levodopa + levomepromazine (1),
levodopa + olanzapine (1)
Other 22 (16.7)
a Referring to the patients with one or more pDDI (n=86)
b Data are presented as median (range)
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Table 3 Prevalence of ADRs with a definite, probable, or possible causality rating in 400 patients with liver cirrhosis
ADR Number of ADRs (total; according to
Child Pugh A, B, C)
Drugs associated with ADRsa (cases according to Child Pugh A, B, C)b
Total ADR 200 (100.0%) Spironolactone (9, 11, 30), torasemide (5, 7, 20), furosemide (4, 1, 10),
ibuprofen (1, 4, 6)
Child Pugh A 46 (23.0%)
Child Pugh B 68 (34.0%)
Child Pugh C 86 (43.0%)
Number of ADR per patientc,d 1 (1–5)
Child Pugh A 1 (1–5)
Child Pugh B 1 (1–5)
Child Pugh C 1.5 (1–5)
Patients with ≥1 ADR 112 (28% of all patients)
Child Pugh A 25 (35.7% of Child Pugh A patients)
Child Pugh B 41 (26.1% of Child Pugh B patients)
Child Pugh C 46 (26.6% of Child Pugh C patients)
ADR with definite/probable
causality rating
24 (12.0%) (8, 11, 5) Spironolactone (3, 1, 1), phenprocoumon (0, 4, 0),
ibuprofen (0, 1, 3), acetylsalicylic acid low dose (1, 3, 0)
ADRs with possible causality
rating
176 (88.0%) (38, 57, 81) Spironolactone (6, 10, 29), torasemide (3, 7, 19),
furosemide (3, 1, 10), propranolol (2, 2, 3)
ADRs as a reason for
hospital admission
16 (8.0%) (6, 5, 5) Spironolactone (3, 0, 1), acetylsalicylic acid low dose (1, 2, 0),
ibuprofen (0, 0, 3), torasemide (2, 0, 1), perindopril (2, 0, 0),
phenprocoumon (0, 2, 0)
ADRs due to ≥1 DDI 15 (7.5%) (6, 7, 2) Major: Spironolactone + ACE inhibitors (1, 0, 1), opiates + benzodiazepines
(1, 1, 0), acetylsalicylic acid low dose + dalteparin (0, 1, 0), acetylsalicylic
acid low dose + phenprocoumon (0, 1, 0), dalteparin + ibuprofen (1, 0, 0),
diltiazem + betablockers (2, 0, 0), amiodarone + propranolol (0, 1, 0)
ADR due to DDI causing
hospital admission
3 (2.0%) (1, 2, 0) Acetylsalicylic acid low dose + phenprocoumon (0, 1, 0),
perindopril + spironolactone (1, 0, 0), amiodarone + propranolol (0, 1, 0)
ADR according to system organ class
Metabolic and
nutritional disorders
54 (27.0%) (13, 13, 28) Spironolactone (4, 6, 17), torasemide (1, 2, 6), furosemide (3, 0, 3),
hydrochlorothiazide (1, 2, 0), chlortalidone (3, 0, 0),
amiloride (0, 3, 0), ramipril (0, 0, 2), enalapril (0, 2, 0)
Gastro-intestinal system
disorders
30 (15.0%) (6, 13, 11) Acetylsalicylic acid low dose (1, 4, 0) and analgesic (1, 1, 1),
ibuprofen (0, 2, 3), mefenamic acid (1, 2, 1), iron (0, 2, 1),
spironolactone (0, 0, 3), phenprocoumon (0, 2, 0)
Urinary system disorders 25 (12.5%) (3, 9, 13) Torasemide (2, 3, 8), spironolactone (2, 2, 6), furosemide (0, 1, 4),
enalapril (0, 1, 1), lisinopril (1, 0, 1)
Cardiovascular disorders,
general
16 (8.0%) (6, 3, 7) Furosemide (1, 0, 2), amlodipine (2, 0, 1), diltiazem (2, 0, 0),
ramipril (0, 1, 1), spironolactone (1, 0, 1), torasemide (0, 0, 2)
Central and peripheral
nervous system disorders
15 (7.5%) (1, 6, 8) Zolpidem (1, 0, 2), oxazepam (0, 1, 1), propranolol (0, 0, 2),
ropinirole (0, 2, 0), spironolactone (0, 1, 1), torasemide (0, 1, 1)
Liver and biliary system
disorders
10 (5.0%) (1, 3, 6) Spironolactone (1, 1, 1), enalapril (0, 1, 1)
Psychiatric disorders 10 (5.0%) (4, 4, 2) Midazolam (1, 0, 1), oxazepam (0, 2, 0), propranolol (1, 1, 0),
zolpidem (1, 0, 1)
Platelet, bleeding and
clotting disorders
10 (5.0%) (3, 5, 2) Spironolactone (1, 0, 1), torasemide (1, 0, 1)
Red blood cell disorders 8 (4.0%) (2, 2, 4) Ibuprofen (0, 1, 2), torasemide (1, 0, 2)
Heart rate and rhythm
disorders
4 (2.0%) (1, 2, 1) -e
Other 18 (9.0%) (6, 8, 4) -e
aMost frequent drugs associated with ADR mentioned
b Sum of cases may exceed the number of ADRs (more than one drug can cause the same ADR)
c Referring to the patients with one or more ADRs (n=112)
d Data are presented as median (range)
e No drug responsible for more than one case
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betablocker prescriptions, only 12 ADRs (hypotension,
syncope, confusion) were identified in nine patients (6%
of all patients with a betablocker, Fig. 1).
Cirrhotic patients with one or more ADR
compared with cirrhotic patients without an ADR
When comparing patients with ADRs to those without
ADRs (Table 4), patients with ADRs were significantly
older than those without ADRs (61 vs. 58 years, p<0.05),
had a lower creatinine clearance (64.3 vs. 91.6 ml/min, p<
0.001), had more total diagnoses (6.38 vs. 5.91, p<0.05),
as well as more non-liver-associated diagnoses (4.20 vs.
3.77, p<0.05). They had more drugs prescribed (6 vs. 4, p<
0.001), as well as more drugs with predominantly
hepatic elimination (4 vs. 3, p<0.001). Patients with ≥1
hepatically eliminated drug were more prevalent in the
ADR group (99.1 vs. 81.6%, p<0.001). The same was true
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Fig. 1 Number of prescriptions,
adverse drug reactions (ADRs),
and patients with ADRs for
specific drug classes. NSAIDs
Nonsteroidal anti-inflammatory
drugs, ACEIs angiotensin-
converting enzyme inhibitors,
ARBs angiotensin receptor
blockers
Table 4 Cirrhotic patients with one or more ADRs in comparison with cirrhotic patients without an ADR
Characteristics Patients with ADR (n=112) Patients without ADR (n=288) p-value
Age (years)a 61 (35–88) 58 (21–87) 0.017
Male 77 (68.8%) 197 (68.4%) 0.947
Creatinine clearance (ml/min)a, b 64 (9–290) 92 (9–280) 0.001
BMI (kg/m2)a, c 24.3 (16.0–42.0) 24.9 (13.5–47.2) 0.997
Child Pugh classification 0.282
Child Pugh A 25 (22.3%) 45 (15.6%)
Child Pugh B 40 (35.7%) 117 (40.6%)
Child Pugh C 47 (42.0%) 126 (43.8%)
Diagnoses per patienta 6 (3–10) 6 (1–10) 0.036
Drugs per patient 6 (0–15) 4 (0–18) <0.001
Drugs with Q0 ≥0.5 per patient 4 (0–12) 3 (0–16) <0.001
Patients with ≥1 hepatically eliminated drug 111 (99.1%) 235 (81.6%) <0.001
Number of pDDIs per patient 0 (0–5) 0 (0–5) 0.012
Patients with ≥1 pDDI 35 (31.3%) 51 (17.8%) 0.004
Length of hospital stay (days)a 12 (1–77) 14 (2–116) 0.984
Patients died during hospitalization 23 (20.5%) 44 (15.3%) 0.233
Cause of cirrhosis 0.056
Alcohol 87 (77.7%) 192 (66.7%)
Viral hepatitis 9 (8.0%) 45 (15.6%)
Both 7 (6.3%) 32 (11.1%)
a Data are presented as median (range)
b Due to incomplete data (body weight, serum creatinine), n=107 and 279 for patients with and without ADR, respectively
c Due to incomplete data (body weight, height), n=63 and 186 for patients with and without ADR, respectively
Eur J Clin Pharmacol (2012) 68:179–188 185
for patients with ≥1 pDDI at hospital admission (31.3 vs.
17.8%). Furthermore, pDDIs were more prevalent in
patients with ADRs than in the control group (0.50 vs.
0.26 per patient, p<0.05).
Discussion
Studies on patients with liver cirrhosis focusing on drug therapy
and drug related problems are scarce in the literature. Lucena et
al. investigated prescribing patterns and drug use in patients
with liver cirrhosis [15, 16]. To prevent or treat complications
of cirrhosis, diuretics, anti-ulcer drugs, laxatives, and vitamin
K were the drugs prescribed most often [15]. Frequent
medications for nonhepatic comorbidities consisted of insulin,
oral antidiabetics, cardiovascular drugs (calcium antagonists,
ACE inhibitors, angiotensin receptor blockers), as well as
drugs for the nervous (anxiolytics, hypnotics) and respiratory
system [16]. The medication pattern of the patients in our
study was similar to the patients reported by Lucena et al. [15,
16], suggesting that these studies reliably reflect the medica-
tion pattern in cirrhotic patients.
Every fifth patient in our study population had a pDDI,
every fourth had an ADR, and 8% of the patients were
hospitalized due to an ADR. This is in line with the 5–10%
prevalence for ADR-related hospitalizations found in the
meta-analysis by Lazarou et al. [17], but slightly more than
the 5.1–6.5% reported in a retrospective cohort study [18]
and in a prospective observational study [19]. Compared to
patients without ADRs, patients with ADRs had more
diagnoses and more drugs prescribed, received more drugs
eliminated hepatically, had more pDDIs, and had a more
compromised renal function.
Polypharmacy is a known risk factor for ADRs [11, 20,
21] and DDIs [22, 23]. Our data indicate that cirrhotic
patients who have more comorbidities have more drugs
prescribed and are therefore at a higher risk for ADRs. The
relationship between number of diagnoses and number of
drugs prescribed is well established [23]. The resulting
polypharmacy is a risk factor for pDDIs [22, 23] and also
for ADRs [11, 20, 21], which may be related to DDIs.
Our data suggest also that treatment with drugs with
predominantly hepatic elimination is a risk factor for ADRs.
More than 50% of the drugs used in our study fall into this
category. Patient exposure to such drugs may be increased
mostly due to elevated oral bioavailability and/or decreased
hepatic clearance, possibly leading to an increased incidence
of dose-dependent ADRs [2]. Astonishingly, systematic
publications focusing on hepatically eliminated drugs as a
risk factor for ADRs in patients with liver disease are
lacking. The drugs with predominantly hepatic elimination
associated with ADRs in our population were mostly
cardiovascular drugs (torasemide, spironolactone, proprano-
lol, amlodipine, diltiazem), NSAIDs (ibuprofen, acetylsali-
cylic acid, mefenamic acid), phenprocoumon, and
benzodiazepines or related agents (midazolam, oxazepam,
zolpidem). If possible, such drugs should be started at a low
dose with careful up-titration until reaching a satisfactory
drug response or toxicity.
A further risk factor for ADRs is impaired renal
function. Impaired glomerular filtration is a well known
risk factor for ADRs also in other populations such as the
elderly [11, 24]. In our study, patients with ADRs had a
lower creatinine clearance as compared to patients without
ADRs. Impaired glomerular filtration may be associated
with decreased renal clearance and increased exposure to
drugs with a predominantly renal excretion. Importantly,
patients with liver cirrhosis and ascites can have a
creatinine clearance <60 ml/min in spite of a normal serum
creatinine [25], mostly due to impaired hepatic formation of
creatine and increased tubular secretion of creatinine [2,
26]. Since the Cockcroft formula may overestimate the
creatinine clearance in cirrhotic patients, drugs with
predominantly renal elimination and dose-dependent ADRs
should be dosed very carefully in cirrhotic patients [2].
Another important risk factor for ADRs is the presence of
pDDIs. In our study, 7.5% of all ADRs were due to a DDI and
12.9% of the DDIs resulted in an ADR. In a recent review of
hospitalized patients on different wards, 17% (range 5–31%)
of all ADRs were reported to be due to DDIs [11]. In patients
with hematopoietic stem cell transplantation (HSCT), 16% of
the ADRs were caused by a DDI and 33% of all DDIs
resulted in an ADR [14]. A comparison of the findings in
patients with liver cirrhosis suggests that the DDIs in
cirrhotics are less severe compared to DDIs in patients with
HSCT. This is due to the fact that imidazole and triazole
antimycotics used in patients with HSCT are CYP
inhibitors interacting with immunosuppressants such as
cyclosporin and tacrolimus, which are used routinely in
HSCT patients. Nevertheless, pDDIs possibly resulting in
severe ADRs are present also in cirrhotic patients; they
are known and should be avoided.
The drugs most frequently involved in ADRs and pDDIs
in our patients were ACE inhibitors, diuretics, NSAIDs,
and oral anticoagulants. ACE inhibitors predispose cirrhotic
patients to electrolyte disturbances and renal ADRs. The
risk for hyperkalemia in cirrhotic patients treated with ACE
inhibitors is increased 5.2-fold compared to patients
without liver disease [27]. Patients with liver cirrhosis and
portal hypertension have an activation of the renin
angiotensin aldosterone system (RAAS) and of the sympa-
thetic nervous system, leading to renal vasoconstriction,
impaired renal perfusion and glomerular filtration [28], and
increased sodium retention [29]. Since drugs interfering
with the RAAS such as ACE inhibitors or sartans can
further impair glomerular filtration due to reduced filtration
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pressure, they should be used very cautiously in cirrhotic
patients. Nevertheless, ACE inhibitors and sartans are
prescribed frequently in cirrhotic patients [16].
NSAIDs and COX-2 inhibitors block renal production of
prostaglandins, possibly leading to impaired renal perfusion
and glomerular filtration, sodium retention, and increase in
ascites [2, 10]. Furthermore, NSAIDs may be associated
with bleeding from esophageal varices and/or gastrointes-
tinal ulcers due to their toxic effects on gastrointestinal
epithelia and inhibition of thrombocyte function. In a case-
control study including patients with esophageal varices
with or without variceal bleeding, the use of NSAIDs in the
week prior to the index day was significantly more
common in bleeding patients (OR=2.8) [30]. Taking into
account the risks for gastrointestinal bleeding, deterioration
of renal function and increase in ascites, it is astonishing
that 7% of our patients used NSAIDs and 2% analgesic
aspirin. A clearer communication of the risks associated
with the use of these drugs and of the analgesic alternatives
in this population is therefore necessary.
Our study has several limitations. A first limitation is the
retrospective character of the study. The elaborated data were
therefore limited to the information provided in the medical
records, and it was sometimes not possible to obtain more
information on the patient’s situation or drug history prior to
hospitalization. A second limitation is the limited sample size,
which resulted in relatively small numbers of ADRs and
DDIs. Nevertheless, we are convinced that the study provides
important safety data in patients with liver cirrhosis and helps
in identifying medication risks.
From the data of our study, we conclude that patients with
liver cirrhosis have many comorbidities predisposing them to
polypharmacy, which is associated with pDDIs and ADRs.
Besides polypharmacy, important risk factors for ADRs in
cirrhotic patients are lack of dose adjustment of drugs
eliminated predominantly by the liver or by the kidney and
certain pDDIs. Hepatologists should therefore not only know
the principles of dose adjustment in patients with liver and/or
renal failure, but also the most important DDIs of the drugs
used to treat liver disease and comorbidities in this population.
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